Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET

NAActive, not recruitingINTERVENTIONAL
Enrollment

1,507

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2030

Conditions
Breast Cancer
Interventions
OTHER

Arm B, tumor markers assessment

Tumor markers assessment every three months through the study or until disease recurrence

Trial Locations (7)

30035

ASL13 - Presidio Ospedaliero Mirano, U.O.C. Oncologia ed Ematologia Oncologica, Mirano

39012

Azienda Sanitaria dell'Alto Adige - Ospedale di Merano, Merano

39042

Azienda Sanitaria dell'Alto Adige - Ospedale di Bressanone, Brixen

39100

Azienda Sanitaria dell'Alto Adige - Ospedale Centrale di Bolzano, Bolzano

40138

Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii, Bologna

42123

IRCCS Azienda Ospedaliera S. Maria Nuova di Reggio Emilia, Reggio Emilia

44124

Azienda Ospedaliero-Universitaria di Ferrara, Ferrara

All Listed Sponsors
collaborator

PONS-S (Patientenorientierte Nachsorge-Stiftung), Augsburg, Germany

UNKNOWN

collaborator

Azienda ULSS 12 Veneziana

OTHER

collaborator

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

lead

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER

NCT02261389 - Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET | Biotech Hunter | Biotech Hunter